A Phase 2 Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics/Effiacacy of Edi200, An Eda-A1 Replacement Protein, Administered to Male Infants with X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Protocol

Investigator: Ophir Klein, MD, PhD
Sponsor: Edimer Pharmaceuticals

Location(s): United States


This Phase 2 first-in-neonate EDI200 study will enroll treatment-naïve, XLHED-affected male newborns in the first two weeks of life. All subjects will meet entry criteria including documentation of an Ectodysplasin (EDA) mutation associated with XLHED. Following Baseline evaluations, EDI200 dosing will be initiated between day-of-life 2 and 14, with each study subject receiving 2 doses/week for a total of 5 doses. The study will enroll subjects in two cohorts with subjects in cohort 1 dosed at 3 mg/kg/dose, associated with partial efficacy, and cohort 2 dosed at 10 mg/kg/dose where enhanced efficacy was demonstrated in the most relevant preclinical model. Given the challenge of identifying families where the subject is yet to be born, it is expected that cohort size and time for recruitment will be variable.